Anna Picciolo-Lehrke

Dr. Picciolo-Lehrke, PhD, heads up the Business Development Neurology at UCB. She was the Business Development lead in the acquisitions of Zogenix, Ra Pharma and Engage as well as in the collaboration agreement with Roche on UCB’s anti-Tau antibody for Alzheimer’s disease and with Novartis on UCB’s alpha synuclein assets for Parkinson’s disease. Dr. Picciolo-Lehrke has a proven track record in partnering and licensing that stems from 20 years professional experience. Prior to joining UCB, she was member of the Business Development and Licensing team at Schwarz Pharma. Since then, she took on various roles in Business Development and Licensing at UCB. Previously, she worked for the Technology Transfer Office of the German Cancer Research Center in Heidelberg, Germany, being responsible for the protection and commercialization of research results arising from research activities.